Paragon Care Ltd - Asset Resilience Ratio

Latest as of June 2020: 0.00%

Paragon Care Ltd (PGC) has an Asset Resilience Ratio of 0.00% as of June 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read PGC total debt and obligations for a breakdown of total debt and financial obligations.

Liquid Assets

AU$0.00
≈ $0.00 USD Cash + Short-term Investments

Total Assets

AU$292.17 Million
≈ $206.73 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2000–2024)

This chart shows how Paragon Care Ltd's Asset Resilience Ratio has changed over time. See Paragon Care Ltd (PGC) net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Paragon Care Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see PGC company net worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$0.00 0%
Short-term Investments AU$0.00 0%
Total Liquid Assets AU$0.00 0.00%

Asset Resilience Insights

  • Limited Liquidity: Paragon Care Ltd maintains only 0.00% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company maintains a balanced mix of cash and short-term investments.

Paragon Care Ltd Industry Peers by Asset Resilience Ratio

Compare Paragon Care Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Sigma Healthcare Ltd
AU:SIG
Medical Distribution 0.03%
Ebos Group Ltd
AU:EBO
Medical Distribution 0.00%
Mayne Pharma Group Ltd
AU:MYX
Medical Distribution 4.00%
Cyclopharm Ltd
AU:CYC
Medical Distribution 1.98%
Profarma Distribuidora de Produtos Farmacêuticos S.A
SA:PFRM3
Medical Distribution 4.48%
Shanghai Pharmaceuticals Holding Co Ltd
SHG:601607
Medical Distribution 4.44%
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
SHG:600332
Medical Distribution 5.56%
Jointown Pharmaceutical Group Co Ltd
SHG:600998
Medical Distribution 0.08%

Annual Asset Resilience Ratio for Paragon Care Ltd (2000–2024)

The table below shows the annual Asset Resilience Ratio data for Paragon Care Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-06-30 0.06% AU$719.00K
≈ $508.74K
AU$1.13 Billion
≈ $800.18 Million
--
2020-06-30 0.00% AU$0.00
≈ $0.00
AU$292.17 Million
≈ $206.73 Million
--
2019-06-30 0.01% AU$22.00K
≈ $15.57K
AU$384.20 Million
≈ $271.84 Million
0.00pp
2018-06-30 0.01% AU$21.00K
≈ $14.86K
AU$349.75 Million
≈ $247.47 Million
-11.17pp
2017-06-30 11.17% AU$18.56 Million
≈ $13.13 Million
AU$166.05 Million
≈ $117.49 Million
--
2016-06-30 0.00% AU$0.00
≈ $0.00
AU$147.79 Million
≈ $104.57 Million
--
2015-06-30 0.65% AU$264.06K
≈ $186.84K
AU$40.59 Million
≈ $28.72 Million
-0.13pp
2013-06-30 0.78% AU$142.80K
≈ $101.04K
AU$18.39 Million
≈ $13.01 Million
+0.56pp
2010-06-30 0.22% AU$26.11K
≈ $18.48K
AU$11.80 Million
≈ $8.35 Million
-41.01pp
2009-06-30 41.24% AU$1.63 Million
≈ $1.16 Million
AU$3.96 Million
≈ $2.80 Million
+40.20pp
2008-06-30 1.03% AU$13.88K
≈ $9.82K
AU$1.34 Million
≈ $950.81K
-1.09pp
2001-06-30 2.12% AU$225.00K
≈ $159.20K
AU$10.59 Million
≈ $7.50 Million
-12.44pp
2000-06-30 14.56% AU$911.99K
≈ $645.29K
AU$6.26 Million
≈ $4.43 Million
--
pp = percentage points

About Paragon Care Ltd

AU:PGC Australia Medical Distribution
Market Cap
$175.69 Million
AU$248.30 Million AUD
Market Cap Rank
#17044 Global
#494 in Australia
Share Price
AU$0.15
Change (1 day)
-3.23%
52-Week Range
AU$0.15 - AU$0.44
All Time High
AU$0.77
About

Paragon Care Limited distributes medical equipment, devices, and consumable products in Australia, New Zealand, and Asia. The company designs, manufactures, and distributes reagent red blood cells, monoclonal blood grouping reagents, and ancillary products for immunohematology laboratories; offers ophthalmology and optometry, neonatal vision screening solutions, and procedural kits. It also provi… Read more